We recently reported a germline deletion polymorphism in the BIM gene that was sufficient to mediate intrinsic resistance to targeted therapies in cancer, including the examples of imatinib (IM) in CML and EGFR inhibitors in EGFR-mutated non-small cell lung cancer (EGFR-NSCLC) [1]. Here, BCL2L11 is linked to non-small cell lung carcinoma.